IDH1 and glioma: Moreover, the assessment of the IDH-1 and -2 status will become crucial since vorasidenib, a new oral brain-penetrant IDH-1/2 inhibitor inhibitor, showed linical activity in IDH-mutant gliomas [58]; therefore, its assessment will be relevant in order to treat patients with appropriate targeted treatments.